Genetic counseling

Virginia Cancer Specialists Continues to Increase Access to Care in New, Expanded Fair Oaks, VA, Location, Now Open

Retrieved on: 
Thursday, May 2, 2024
Brain, Cancer, Genetics, Palliative care, Blood, Fairfax County Parkway, Suite, I-66, Elective surgery, Estate (law), Breast, Oncology, Research, FACS, Patient, Physician, Lung, Route, Social, Diagnosis, Radiation, Quality of life, Hematology, Genetic counseling, Breast cancer, Nursing

FAIRFAX, Va., May 2, 2024 /PRNewswire/ -- Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, reinforces its commitment to providing exceptional cancer care and progressing clinical cancer research by expanding its third location in the last 6 months. Virginia Cancer Specialists serves patients in 10 locations throughout Northern Virginia with advanced, integrated, complete cancer care.

Key Points: 
  • Now in its 52nd year, Virginia Cancer Specialists continues to increase service and access to quality cancer care throughout Northern Virginia.
  • FAIRFAX, Va., May 2, 2024 /PRNewswire/ -- Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, reinforces its commitment to providing exceptional cancer care and progressing clinical cancer research by expanding its third location in the last 6 months.
  • Virginia Cancer Specialists serves patients in 10 locations throughout Northern Virginia with advanced, integrated, complete cancer care.
  • Founded in 1972, Virginia Cancer Specialists has been an integral part of the Northern Virginia medical community for over 50 years.

University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs

Retrieved on: 
Wednesday, April 10, 2024
Colorectal surgery, Cancer, Gastroenterology, Gastrointestinal disease, Hope, Pancreatic cancer, Hematology, UHA, Communication, Partnership, Research, UCBC, Oncology, History, Patient, Physician, Radiation, Genetic counseling, Nursing

University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years.

Key Points: 
  • University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years.
  • University Health Alliance University Health Alliance allows access to comprehensive, world-class healthcare in the greater Athens area.
  • University Health Alliance is brought to you by the trusted team at University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia.
  • University Health Alliance is a division of University Cancer & Blood Center, LLC.

Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights

Retrieved on: 
Thursday, April 25, 2024
Oncology, Data Management, Health, Technology, Genetics, Artificial Intelligence, Biotechnology, Cancer, Sequence, Genetic testing, Disease, Patient, Genome, Diagnosis, Whole genome sequencing, Genetic counseling

Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.

Key Points: 
  • Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
  • The clinical use of whole genome sequencing has relatively been limited due to cost and technology barriers.
  • “This milestone solidifies our position as the whole-genome precision health leader.”
    Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.
  • The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone.

Parkinson’s Foundation and Tasso Announce Partnership to Accelerate Parkinson’s Disease Genetics Research

Retrieved on: 
Tuesday, April 23, 2024
Data Management, Technology, Health, Philanthropy, Seniors, Neurology, Health Technology, Infectious Diseases, Genetics, Foundation, Consumer, Science, Parkinson's disease, GP2, Partnership, Collection, Doctor of Philosophy, Research, Coalition, Genetic testing, Disease, Senior, Patient, Physician, Data collection, ASAP, Multimedia, PD, Genetic counseling, Gene, Pharmaceutical industry

The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD).

Key Points: 
  • The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD).
  • The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s .
  • The goal of the research is to screen the collected samples for mutations among select, clinically relevant PD genes.
  • “Tasso and the Parkinson’s Foundation share a mission to accelerate life-changing research,” said Ben Casavant, PhD, CEO and co-founder of Tasso.

Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing

Retrieved on: 
Thursday, April 25, 2024
University, Risk, Public health, Health, FACMG, Partnership, Parent, Research, Workflow, RTI International, NGS, Medicine, SVP, Therapy, Genetic counseling, Organization, Gene, RTI, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and WALTHAM, Mass., April 25, 2024 /PRNewswire/ -- RTI International today announced that Early Check, a groundbreaking research study that provides free voluntary health tests for newborns up to four weeks old in North Carolina, has chosen Revvity, Inc. to conduct genome sequencing for the study starting in May.

Key Points: 
  • The agreement with Revvity will allow Early Check to continue to test newborns for hundreds of childhood-onset rare genetic conditions , many of which are not included in North Carolina's standard newborn screening, as the study assesses critical questions about when and how to integrate genome sequencing into universal newborn screening.
  • "Revvity has a proven track record in newborn screening and conducting sequencing with accuracy and efficiency, which are critical to the success of this research study."
  • Revvity's genome sequencing workflow is powered by the AVITI™ System , an innovative and emerging genome sequencing platform developed by Revvity's partner Element Biosciences, Inc. Revvity's workflow includes sample-to-answer that saves time and effort required for genomic sample analysis.
  • Early Check began offering genome sequencing in September 2023 .

Getlabs and Inocras Partner to Create a Seamless Patient Experience for Cancer and Rare Disease Testing

Retrieved on: 
Wednesday, April 24, 2024
Genome, Health, Organization, Patient, Cancer, Partnership, Genetic counseling, Travel, Medical device

Inocras provides whole genome sequencing tests, which deliver patients deep insights into their cancer and rare disease by providing comprehensive and detailed analyses of an individual's genetic composition.

Key Points: 
  • Inocras provides whole genome sequencing tests, which deliver patients deep insights into their cancer and rare disease by providing comprehensive and detailed analyses of an individual's genetic composition.
  • By embedding Getlabs' at-home lab collection services within Inocras's intuitive end-to-end patient testing process, this partnership promises a unique and enhanced experience for patients, who will benefit from its convenience and efficiency.
  • "We are thrilled to embark on this partnership with Inocras," said Kyle Michelson, CEO of Getlabs.
  • The partnership between Getlabs and Inocras represents a powerful collaboration between two industry leaders committed to enhancing the patient experience through accessibility, convenience and efficiency.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Retrieved on: 
Friday, March 15, 2024
Research, WGS, Automation, Genomics, Absorption, Health, Development, Growth, Exercise, Nebula Genomics, COVID-19, Patient, PMI, RNA, Sale, Acquisition, Public expenditure, Food, Engineering, Insurance, Protein, Diagnosis, RNA-Seq, Omicron, Prophase, HRSA, Whole genome sequencing, Marketing, FDA, Genetic counseling, Cryptocurrency

Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.

Key Points: 
  • With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
  • This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
  • Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
  • Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

Retrieved on: 
Friday, March 29, 2024
Genetic testing, Partnership, Physician, Patient, Fertility, Insurance, Inception, FDA, LH, Genetic counseling

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Key Points: 
  • The expansion of this partnership delivers another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient service centers.
  • Additionally, Labcorp offers comprehensive genetic counseling, services for provider questions, and complimentary review of carrier screening results for patients.
  • To improve financial access to genetic carrier screening for the U.S. patient population, Labcorp is contracted with many insurance companies.
  • "Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and Director of Genetic Services at Inception.